These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 28728094

  • 1. Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain.
    Rejas-Gutiérrez J, Bruguera E, Cedillo S.
    Eur Psychiatry; 2017 Sep; 45():41-49. PubMed ID: 28728094
    [Abstract] [Full Text] [Related]

  • 2. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.
    Jiménez-Ruiz CA, Solano-Reina S, Signes-Costa J, de Higes-Martinez E, Granda-Orive JI, Lorza-Blasco JJ, Riesco-Miranda JA, Altet-Gomez N, Barrueco M, Oyagüez I, Rejas J, SESEPARAR’s Integrated Tobacco Research Program.
    Int J Chron Obstruct Pulmon Dis; 2015 Sep; 10():2027-36. PubMed ID: 26451100
    [Abstract] [Full Text] [Related]

  • 3. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
    Cedillo S, Sicras-Mainar A, Jiménez-Ruiz CA, Fernández de Bobadilla J, Rejas-Gutiérrez J.
    Eur Addict Res; 2017 Sep; 23(1):7-18. PubMed ID: 27794567
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.
    Trapero-Bertran M, Muñoz C, Coyle K, Coyle D, Lester-George A, Leidl R, Németh B, Cheung KL, Pokhrel S, Lopez-Nicolás Á.
    Addiction; 2018 Jun; 113 Suppl 1(Suppl Suppl 1):65-75. PubMed ID: 29532966
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [Abstract] [Full Text] [Related]

  • 7. Cost-benefit analysis of funding smoking cessation before surgery.
    Jiménez-Ruiz CA, Martín V, Alsina-Restoy X, de Granda-Orive JI, de Higes-Martínez E, García-Rueda M, Genovés-Crespo M, López-García C, Lorza-Blasco JJ, Márquez FL, Ramos-Pinedo Á, Riesco-Miranda JA, Signes-Costa J, Solano-Reina S, Vaquero-Lozano P, Rejas J.
    Br J Surg; 2020 Jul; 107(8):978-994. PubMed ID: 32372474
    [Abstract] [Full Text] [Related]

  • 8. [Economic evaluation of pharmacotherapies for smoking cessation].
    Antoñanzas F, Portillo F.
    Gac Sanit; 2003 Jul; 17(5):393-403. PubMed ID: 14599422
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M, Welsing P, Rutten-van Mölken MP.
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [Abstract] [Full Text] [Related]

  • 10. Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.
    Keeney E, Welton NJ, Stevenson M, Dalili MN, López-López JA, Caldwell DM, Phillippo DM, Munafò MR, Thomas KH.
    Value Health; 2021 Jun; 24(6):780-788. PubMed ID: 34119075
    [Abstract] [Full Text] [Related]

  • 11. Economic Impact of Financial Incentives and Mailing Nicotine Patches to Help Medicaid Smokers Quit Smoking: A Cost-Benefit Analysis.
    Sung HY, Penko J, Cummins SE, Max W, Zhu SH, Bibbins-Domingo K, Kohatsu ND.
    Am J Prev Med; 2018 Dec; 55(6 Suppl 2):S148-S158. PubMed ID: 30454669
    [Abstract] [Full Text] [Related]

  • 12. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [Abstract] [Full Text] [Related]

  • 13. Budgetary impact of varenicline in smoking cessation in the United Kingdom.
    Taylor DC, Chu P, Rosen VM, Baker CL, Thompson D.
    Value Health; 2009 Feb; 12(1):28-33. PubMed ID: 18637141
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand.
    Tosanguan J, Chaiyakunapruk N.
    Addiction; 2016 Feb; 111(2):340-50. PubMed ID: 26360507
    [Abstract] [Full Text] [Related]

  • 16. Funding a smoking cessation program for Crohn's disease: an economic evaluation.
    Coward S, Heitman SJ, Clement F, Negron M, Panaccione R, Ghosh S, Barkema HW, Seow C, Leung YP, Kaplan GG.
    Am J Gastroenterol; 2015 Mar; 110(3):368-77. PubMed ID: 25350768
    [Abstract] [Full Text] [Related]

  • 17. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan.
    Igarashi A, Takuma H, Fukuda T, Tsutani K.
    Pharmacoeconomics; 2009 Mar; 27(3):247-61. PubMed ID: 19354344
    [Abstract] [Full Text] [Related]

  • 18. [Cost effectiveness analysis of varenicline (Champix) for the treatment of smoking in Spain].
    Fernández de Bobadilla Osorio J, Sánchez-Maestre C, Brosa Riestra M, Arroyo O, Sanz de Burgoa V, Wilson K.
    An Med Interna; 2008 Jul; 25(7):342-8. PubMed ID: 19295994
    [Abstract] [Full Text] [Related]

  • 19. Healthcare Costs of Smokers Using Varenicline Versus Nicotine-Replacement Therapy Patch in the United States: Evidence from Real-World Practice.
    Lee LJ, Li Q, Bruno M, Emir B, Murphy B, Shah S, Reynolds M, Marchant N, Park PW.
    Adv Ther; 2019 Feb; 36(2):365-380. PubMed ID: 30569324
    [Abstract] [Full Text] [Related]

  • 20. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
    von Wartburg M, Raymond V, Paradis PE.
    Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.